Editor’s Note: “Every drug can be made and every disease can be treated”. Over the past 25 years, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision. 

In tribute to the journey and in celebration of new beginnings, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

An email arrived in Dr. Ke Chen’s inbox. The head of API Late Phase Development and Commercialization at WuXi STA, a subsidiary of WuXi AppTec opened it and began reading. She was expecting a routine update. Instead, the message took her by surprise. 

A partner, in negotiations to license a promising drug from a biotech company, had requested WuXi STA to handle the manufacturing. Chen’s team had prepared a proposal outlining the expected production timeline. It was a traditional estimate, not even an aggressive one by their internal standards.

Then came the reply: the biotech company refused to move forward.

“Your timeline is nearly three times faster than our current vendor. That’s impossible,” its leadership wrote. “Either the quality will suffer, or you’re exaggerating.”

Rather than defending their credibility with words, Chen and her team turned to scientific demonstration. They proposed a bold experiment: a demonstration batch produced step-by-step under full oversight. Each of the 10 synthetic stages would be paused for the partner’s testing before the next stage began, a gesture of transparency and confidence.

Mid-experiment, the biotech company was convinced: “Let’s move on.” they said. WuXi STA completed the program at the proposed pace, met all specifications, and ultimately saved the client time without compromising quality.

The rights of that drug, now FDA-approved, have since passed through several owners and WuXi STA has remained the trusted drug substance (DS)-to-drug product (DP) integrated supplier.

As Dr. Chen Ke recalled, this was just one of many cases where WuXi AppTec has enabled global clients over the past 25 years. "Breaking through CMC bottlenecks for our clients and getting medicines to patients faster—this is not only our day-to-day practice but also the unwavering goal of our team," she said.

Bridging the D-to-M Transition

In the lifecycle of a drug, few moments are as pivotal, and as rigorous, as the handoff from development (D) to manufacturing (M). When a molecule achieves clinical proof of concept (often in Phase 2 trials), it shifts from scientific exploration to commercial execution, where discovery dreams meet the realities of scale, regulation, and business survival.

“As the D-to-M transition sets the foundation for long-term commercial success, the choice of a manufacturing partner is a strategic decision with multi-year implications,” Chen explains. “The partnership must be built on a foundation of reliability and robustness from the very beginning.”

The core of this rigor is manufacturing validation. Every batch that enters the “M” phase must meet rigorous standards of reproducibility, documentation, and data integrity under the scrutiny of regulators such as the FDA, EMA, and NMPA.

“In a well-executed project, all process data should fall within the expected range.” Chen explained. She further emphasized that a single out-of-specification (OOS) result, even one with no impact on final product quality, can invalidate an entire validation campaign, delaying submission for a year or more, disrupting launch timelines, and postponing patient access to needed therapy.

This is why, as Chen describes, “Quality in late-stage manufacturing is a lifeline.” It demands not only technical expertise but also deep regulatory insight, necessitating a partner proficient in both domains.

WuXi STA has built precisely that record. The team has supported more than 50 first-time, global NDA approvals while maintaining a zero-delay record for CMC filings. Through first three quarters of 2025 alone, the company has enabled eight successful NDAs, with 10 to 11 expected by year-end. Behind those numbers lies deep scientific capability to help clients tackle some of the industry’s most complex small molecules.

To Chen, the consistent quality in late-stage projects is a vital part of WuXi AppTec's commitment to upholding global high standards. Over the past 25 years, WuXi AppTec has established a global quality system that "stands up to inspection anytime, anywhere."

When the Clock Started Ticking

Several years ago, a multinational pharma company had just acquired a therapy whose registered starting material was abruptly challenged by the EMA during review. The situation was critical: the original European CDMO that produced the material couldn’t help.

The EMA’s notice was clear. Within four months, the company had to revalidate the starting material, provide extensive supplementary documentation, and complete a comparability study, or risk rejection of the application altogether. Without approval, the commercial inventory would be stranded and unable to reach patients in urgent need of the drug.

Within hours of receiving the task, Chen and her team mobilized. A 50-person R&D task force was assembled overnight, soon joined by sourcing specialists, analytical scientists, and manufacturing engineers. The technical package they inherited was incomplete, riddled with gaps and inconsistencies. With the EMA clock running and commercial inventory at risk of sitting idle, the team reframed the problem around a single question: how do we prevent patients from waiting longer?

“Failure wasn’t an option,” she recalls.

Working against the clock, WuXi STA reconstructed the chemical process, developed new analytical methods, and produced multiple validation batches. Every result was documented, reviewed, and assembled into a submission-ready package. In just three months, a full month ahead of EMA’s deadline—the company delivered all data required for regulatory review. The client’s comparability tests passed successfully, and the therapy received EMA approval without any delay in market availability.

To outsiders, it appeared a dramatic rescue. To Chen, the experience was less about miracles than about coordination. It revealed how deeply interconnected R&D, manufacturing, and quality functions must be to solve complex challenges at speed, and how an integrated platform can quietly stabilize a demanding situation while keeping innovation on schedule.

The Power of True Integration

The distinction of WuXi STA’s integrated platform lies not in owning multiple sites, but in operating under one global quality system and a unified management mindset: one project, one continuous chain of accountability.

Several years ago, a client developing a cancer treatment chose WuXi STA to take over manufacturing during its early stage clinical trials. In under two and a half years, WuXi STA used its fully connected network to complete every step needed for testing and approval across four sites, covering everything from making the drug substance to developing and producing the tablets.

Had the client divided production steps among separate vendors, each stage would have required independent release testing and material transfer, a process easily extending to four years. Instead, WuXi STA’s teams ran tasks in parallel, passing materials seamlessly between sites. “It wasn’t just about speed,” Chen notes. “It also enhanced safety by ensuring consistent quality control throughout the molecule‘s journey.”

This ability to compress timelines without compromising quality has become the engine of WuXi STA’s global credibility.

“The key differentiator is our truly integrated platform,” Chen concluded. It is this integration that enables WuXi STA to tackle clients’ most complex challenges. “Even for projects with significant technical barriers, tight timelines or demanding CMC challenges, WuXi STA consistently delivers robust and reliable outcomes.”

Vision and the Road Ahead

After 15 years in the industry, Chen’s guiding principle has never wavered: remove bottlenecks from CMC.

“Whether it’s chemistry, analytics, or supply chain, our job is to take CMC off the bottleneck,” she says. “To make sure nothing slows a good drug from reaching patients.”

She pauses, then adds a phrase that could serve as both personal mantra and corporate creed:

“Stay true to our purpose. Move steadily. Bring more medicines to life.” These closing words encapsulate not only her deeply held belief but also the enduring commitment that has characterized WuXi AppTec's 25-year journey: the consistent creation of value for clients, the industry, and patients worldwide.